In a significant advancement for hematological oncology, researchers from Ludwig Cancer Research have identified a promising new therapeutic strategy to…
Read More

In a significant advancement for hematological oncology, researchers from Ludwig Cancer Research have identified a promising new therapeutic strategy to…
Read More
Acute myelogenous leukemia (AML) remains one of the most formidable challenges in modern oncology, characterized by a rapid progression and…
Read More
The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…
Read More
Acute Myelogenous Leukemia (AML) has long remained one of the most formidable challenges in oncology, characterized by its rapid progression…
Read More
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
The landscape of hematological oncology is facing a potential paradigm shift following a landmark study by Ludwig Cancer Research, which…
Read More
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
The landscape of hematological oncology is facing a potential paradigm shift following a comprehensive study led by Ludwig Cancer Research,…
Read More
In a landmark advancement for hematologic oncology, researchers from Ludwig Cancer Research have unveiled a novel therapeutic strategy aimed at…
Read More